Neuraxis Inc
NRXS3.900USD
+1.630+71.81%
Cierre 05/20, 16:00（ET）Cotizaciones retrasadas 15 min
28.14MCap. mercado
PérdidaP/E TTM
Más Datos de Neuraxis Inc Compañía
Neuraxis, Inc. is a medical technology company. The Company is focused on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults. It focuses on advancing science and leveraging evidence-based medicine to drive the adoption of its IB-Stim therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is a food and drug administration (FDA) cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old. The Company’s second product, the Rectal Expulsion Device (RED), is indicated to evaluate the neuromuscular function of a patient’s ability to expel its contents from the rectum and as a qualitative test for rectal hypersensitivity. RED (K242304, 2024) helps identify patients with rectal hypersensitivity who experience a desire or urge defecating at lower volumes of distension.
Información de la empresa
Código de la empresaNRXS
Nombre de la empresaNeuraxis Inc
Fecha de salida a bolsaAug 09, 2023
Fundada en2022
Director ejecutivoMr. Brian Carrico
Número de empleados21
Tipo de seguridadOrdinary Share
Fin del año fiscalAug 09
Dirección11611 N. Meridian St
CiudadCARMEL
Bolsa de valoresNYSE American Consolidated
PaísUnited States of America
Código postal46032
Teléfono18126890791
Sitio Webhttps://neuraxis.com/
Código de la empresaNRXS
Fecha de salida a bolsaAug 09, 2023
Fundada en2022
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Christopher Robin (Chris) Brown
Dr. Christopher Robin (Chris) Brown
Director - Innovation, Founder, Director
Director - Innovation, Founder, Director
792.84K
--
Mr. Brian Carrico
Mr. Brian Carrico
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
20.12K
--
Ms. Kristin A. Ferge
Ms. Kristin A. Ferge
Independent Director
Independent Director
14.34K
+1.11K%
Mr. Dan Clarence
Mr. Dan Clarence
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Timothy R. Henrichs
Mr. Timothy R. Henrichs
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Thomas Carrico
Dr. Thomas Carrico
Chief Regulatory Officer, Compliance Officer and Privacy Officer
Chief Regulatory Officer, Compliance Officer and Privacy Officer
--
--
Ms. Beth Keyser
Ms. Beth Keyser
Independent Director
Independent Director
--
--
Mr. Gil Aharon
Mr. Gil Aharon
Director
Director
--
--
Dr. Adrian Miranda
Dr. Adrian Miranda
Chief Medical Officer, Senior Vice President - Science and Technology
Chief Medical Officer, Senior Vice President - Science and Technology
--
-100.00%
Mr. Bradley Mitch Watkins
Mr. Bradley Mitch Watkins
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Christopher Robin (Chris) Brown
Dr. Christopher Robin (Chris) Brown
Director - Innovation, Founder, Director
Director - Innovation, Founder, Director
792.84K
--
Mr. Brian Carrico
Mr. Brian Carrico
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
20.12K
--
Ms. Kristin A. Ferge
Ms. Kristin A. Ferge
Independent Director
Independent Director
14.34K
+1.11K%
Mr. Dan Clarence
Mr. Dan Clarence
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Timothy R. Henrichs
Mr. Timothy R. Henrichs
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Thomas Carrico
Dr. Thomas Carrico
Chief Regulatory Officer, Compliance Officer and Privacy Officer
Chief Regulatory Officer, Compliance Officer and Privacy Officer
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Accionista
Hora de actualización: sáb., 17 de may
Hora de actualización: sáb., 17 de may
Estadísticas de accionistas
Tipo
Estadísticas de accionistas
Accionista
Proporción
Brown (Christopher Robin)
10.99%
Hannasch (Brian)
10.75%
Creative Planning, Inc.
7.65%
Masimo Corp
7.37%
Parsons Capital Management, Inc.
1.62%
Other
61.63%
Estadísticas de accionistas
Accionista
Proporción
Brown (Christopher Robin)
10.99%
Hannasch (Brian)
10.75%
Creative Planning, Inc.
7.65%
Masimo Corp
7.37%
Parsons Capital Management, Inc.
1.62%
Other
61.63%
Tipo
Accionista
Proporción
Individual Investor
22.97%
Investment Advisor/Hedge Fund
8.74%
Corporation
7.37%
Investment Advisor
1.86%
Bank and Trust
1.48%
Hedge Fund
0.40%
Private Equity
0.28%
Other
56.92%
Participación institucional
Hora de actualización: mar., 4 de mar
Hora de actualización: mar., 4 de mar
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
30
4.17M
57.80%
+470.52K
2024Q4
29
4.04M
56.27%
+476.54K
2024Q3
28
3.89M
54.36%
+476.60K
2024Q2
27
3.62M
51.12%
+229.93K
2024Q1
18
1.89M
32.23%
+1.25M
2023Q4
18
2.14M
36.50%
+1.56M
2023Q3
14
2.07M
34.17%
+2.07M
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Brown (Christopher Robin)
792.84K
10.99%
--
--
Jun 17, 2024
Hannasch (Brian)
682.90K
9.46%
+133.33K
+24.26%
Sep 30, 2024
Masimo Corp
531.55K
7.37%
--
--
Jun 17, 2024
Parsons Capital Management, Inc.
116.73K
1.62%
+103.73K
+797.89%
Dec 31, 2024
BMO Harris Bank N.A.
139.02K
1.93%
-10.00K
-6.71%
Dec 31, 2024
The Vanguard Group, Inc.
27.98K
0.39%
--
--
Dec 31, 2024
Citadel Advisors LLC
47.09K
0.65%
+47.09K
--
Dec 31, 2024
Stifel, Nicolaus & Company, Incorporated
25.71K
0.36%
--
--
Dec 31, 2024
Geode Capital Management, L.L.C.
22.70K
0.31%
--
--
Dec 31, 2024
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
